RESEARCH DESK / LIVING REFERENCE
Morgellons evidence table
What investigators examined. What they observed. What the study can—and cannot—establish.
Version 1.0 · Reviewed October 1, 2026 · Seven questions · Four source papers
The name Morgellons has been applied to people with different combinations of skin lesions, unusual material, skin sensations, and other symptoms. Studies that use different entry criteria and examine different specimens need to be read on their own terms. This table keeps the sample, observation, and inference in separate columns.
It is a research reference, not a diagnostic test or a treatment recommendation. A reported observation deserves investigation; a single study does not settle the cause for everyone.
DEFINED COHORT
The CDC study identified 115 cases; 41 had clinical evaluation.
SELECTED TISSUE
Filament and Borrelia studies examined small, selected groups.
TREATMENT GAP
A 2025 literature search found no Morgellons treatment RCTs.
The evidence, question by question
“What remains open” is our reading of the study design and its limits. Where a row draws on the same participants as another row, it is not a separate replication.
| Question and source | What was examined and observed | What remains open |
|---|---|---|
| How much do symptoms affect daily life? Pearson et al., 2012 Descriptive cohort | Investigators identified 115 Kaiser Permanente Northern California enrollees under a broad case definition. Seventy completed a survey. More than half rated their health fair or poor; physical and mental quality-of-life scores were below national norms. | The burden is measurable in this cohort. The survey cannot by itself identify the cause of symptoms, and its respondents may differ from people who did not take part. |
| What did biopsies show? Pearson et al., 2012 Clinical subset | Forty-one people had clinical evaluation; investigators obtained 62 biopsies, including 37 from lesions. Fifteen of those 37 lesional biopsies showed changes compatible with excoriation or chronic irritation. Some lesions had evidence of secondary infection. | A pattern of rubbing or injury describes the sampled tissue; it does not establish what caused the original sensation or every lesion. The study did not identify one underlying condition shared by the cohort. |
| What was the loose material? Pearson et al., 2012 Material analysis | Twenty-three specimens from intact skin sites in 12 people were analyzed. Many contained protein, likely superficial skin, or cellulose consistent with cotton; some contained other environmental materials. In biopsies, most identified birefringent material lay on the surface, edge, or crust. | These results identify the material that was collected. They do not establish the composition of every reported filament or resolve all tissue-associated findings in other selected studies. |
| Have tissue-associated filaments been described? Middelveen et al., 2013 Four-patient case series | Investigators examined filament-bearing skin material from four selected patients with histologic stains and electron microscopy. They described filaments connected with epithelial tissue and staining consistent with keratin and collagen in their specimens. | The observations merit independent study with prespecified sampling and matched controls. Four selected cases cannot establish how common such structures are, whether they are specific to Morgellons, or what produces them. |
| Is Borrelia associated with selected cases? Middelveen et al., 2015 Twenty-five-patient series | Twenty-five volunteers had provider-documented fibers under, in, or projecting from skin. The authors reported Borrelia identification by PCR and/or in situ hybridization in tissue or culture specimens from 24 of 25; 15 had Borrelia gene products reported in lesion material or skin cultures. Five patients had appeared in earlier case reports. | This is a finding in a selected group, with no matched patient comparison group. It does not establish population prevalence, prove that Borrelia caused the filaments, or demonstrate that antibiotics improve outcomes. Independent replication is a key next test. |
| Do psychological findings settle the diagnosis? Pearson et al., 2012 Clinical subset | Among clinically evaluated participants, 23 of 39 had impairment in at least one cognitive domain and 25 of 40 had a significant elevation on at least one Personality Assessment Inventory clinical scale, most often somatic concerns. | Screening scores document issues that deserve care. They are not a diagnosis of delusional infestation for every participant, and they do not exclude a coexisting skin or medical condition. This is the same CDC cohort, not a new study. |
| Which treatment has been tested rigorously? Akbarialiabad et al., 2025 Literature review | After a search across four databases, the reviewers retained 167 studies for full-text review and found no randomized controlled trial of a Morgellons treatment. They identified one crossover trial for delusional infestation, a different study population. | There is no trial result here that can rank Morgellons-specific treatments. This row summarizes a review rather than adding a new patient cohort; care still needs to address documented findings and symptoms individually. |
What would change this table?
A stronger next study would agree on entry criteria in advance; document intact and affected skin before sampling; use matched comparison groups, standardized collection and blinded analysis; and report results for every enrolled participant. If a proposed treatment follows, prespecified outcomes and a controlled trial are needed to test benefit and harm.
Patient accounts can reveal questions researchers missed, especially the timing and location of sensations and material. They should shape what is measured. Laboratory findings and treatment effects still require their own tests.
Source papers and update notes
- Pearson ML et al. Clinical, epidemiologic, histopathologic and molecular features of an unexplained dermopathy. PLOS ONE. 2012;7:e29908.
- Middelveen MJ et al. Characterization and evolution of dermal filaments from patients with Morgellons disease. Clinical, Cosmetic and Investigational Dermatology. 2013;6:1–21.
- Middelveen MJ et al. Exploring the association between Morgellons disease and Lyme disease. BMC Dermatology. 2015;15:1.
- Akbarialiabad H et al. Morgellons disease: a review on current evidence and the need for consensus, standardized criteria, and future randomized controlled trials. Archives of Dermatological Research. 2025;317:815.
Update rule: Add a dated row or revise one when a new original study tests a listed question, a substantive correction changes a cited paper, or a new systematic review changes the treatment evidence. Record the sample, method, result, and unresolved limitation together. Version 1.0 · October 1, 2026.